Cybin is trading 5.4% up at $7.64 in pre-market, extending last week’s strong gains as investors react to positive clinical developments and a strengthened balance sheet.
- Bullish analyst coverage continues to highlight Phase 3 progress for the company's lead psychedelic candidate targeting depression.
- Recent equity and registered offerings have significantly reinforced the firm's cash position, providing an improved funding runway for its late-stage mental health pipeline.
- The stock's upward momentum reflects a shift in investor focus toward clinical milestones rather than broader macroeconomic volatility.